Novo Nordisk's Q1 numbers are a reminder that the weight-loss drug boom is far from over. The Danish pharma giant reported May 4 that net profit rose 18% to DKK 35 billion, beating analyst expectations on surging sales of Wegovy and Ozempic. The company also lifted its full-year guidance, and shares jumped 4% in early Copenhagen trading.
Wegovy and Ozempic still the engine
Almost all the growth came from the GLP-1 portfolio. In 2026, total sales grew 10% and operating profit 6%, according to the company. Q1 2026 accelerated that, with profit up 18% from a year earlier. The numbers suggest Novo has not yet hit a ceiling on demand for its anti-obesity and diabetes drugs, even as competitors like Eli Lilly push into the same space.
What matters for investors is the raised outlook. By upgrading projections, Novo signals that production capacity and supply constraints are easing. The company also started a DKK 15 billion share repurchase program in February, as reported by Yahoo Finance, returning cash to shareholders while the stock trades near record highs.
What this means for Danish business
Novo Nordisk is not just a company, it is the backbone of the Copenhagen Stock Exchange. The pharma sector accounts for about 20% of Danish exports, and Novo alone makes up roughly a fifth of the entire market cap of Danish equities. When Novo's shares rise 4%, that ripples through pension funds, the krone exchange rate, and government tax revenue.
The Q1 beat also reinforces Denmark's reliance on a single industry. While the country has diversified into wind energy and shipping, Novo's dominance means any stumble would hit the economy hard. For now, the trend is positive: the GLP-1 drug market is still expanding, and Novo holds the leading position.
Expect Novo to keep upgrading guidance through 2026 as it opens new production lines and expands into new markets like China. The real risk is not demand but pricing pressure once more competitors launch. That fight is still a year or two away. For this quarter, Copenhagen has every reason to celebrate.
Read more: Danish April Inflation Data to Influence Rate Outlook.